Aptamer Group PLC (LSE:APTA) — Market Cap & Net Worth
Market Cap & Net Worth: Aptamer Group PLC (APTA)
Aptamer Group PLC (LSE:APTA) has a market capitalization of $205.09K (GBX1.69 Billion) as of May 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30820 globally and #1015 in its home market, demonstrating a 4.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptamer Group PLC's stock price GBX0.63 by its total outstanding shares 2696978377 (2.70 Billion). Analyse Aptamer Group PLC (APTA) cash conversion ratio to see how efficiently the company converts income to cash.
Aptamer Group PLC Market Cap History: 2021 to 2026
Aptamer Group PLC's market capitalization history from 2021 to 2026. Data shows change from $44.14 Million to $205.09K (-71.18% CAGR).
Index Memberships
Aptamer Group PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.02% | #291 of 722 |
Weight: Aptamer Group PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptamer Group PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptamer Group PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.29x
Aptamer Group PLC's market cap is 0.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $44.14 Million | $1.28 Million | -$1.85 Million | 34.48x | N/A |
| 2022 | $16.74 Million | $4.04 Million | -$2.09 Million | 4.15x | N/A |
| 2023 | $377.37K | $1.75 Million | -$7.84 Million | 0.22x | N/A |
| 2024 | $121.41K | $860.00K | -$2.96 Million | 0.14x | N/A |
| 2025 | $352.76K | $1.20 Million | -$2.42 Million | 0.29x | N/A |
Competitor Companies of APTA by Market Capitalization
Companies near Aptamer Group PLC in the global market cap rankings as of May 5, 2026.
Key companies related to Aptamer Group PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Aptamer Group PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Aptamer Group PLC's market cap moved from $44.14 Million to $ 205.09K, with a yearly change of -71.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX205.09K | -41.86% |
| 2025 | GBX352.76K | +190.54% |
| 2024 | GBX121.41K | -67.83% |
| 2023 | GBX377.37K | -97.75% |
| 2022 | GBX16.74 Million | -62.08% |
| 2021 | GBX44.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Aptamer Group PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $205.09K USD |
| MoneyControl | $205.09K USD |
| MarketWatch | $205.09K USD |
| marketcap.company | $205.09K USD |
| Reuters | $205.09K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptamer Group PLC
Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and … Read more